Drug · CHEMBL744

RILUZOLE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. RILUZOLE. Drugs and targets, record CHEMBL744. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL744

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: RILUZOLE; ChEMBL
ChEMBL ID: CHEMBL744; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Exservan, Rilutek, Riluzole zentiva, Teglutik, Tiglutik kit; ChEMBL
Other names: BHV-0223, NSC-753433, NSC-759823, RP 54274, RP-54274, Riluzol, Tiglutik; ChEMBL
DrugBank: DB00740; DrugBank
InChIKey: FTALBRSUTCGOEG-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 1 of its 31 diseases, from DailyMed, EMA Human Drugs and TTD; Open Targets

Targets10

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
SCN10A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6336
SCN11A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/11280
SCN1A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6323
SCN2A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6326
SCN3A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6328
SCN4A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6329
SCN5A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6331
SCN7A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6332
SCN8A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6334
SCN9A	Sodium channel alpha subunit	Sodium channel alpha subunit blocker	BLOCKER	https://conductscience.org/library/genes/6335

Source ChEMBL

Diseases31

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
amyotrophic lateral sclerosis	Approval	DailyMed, EMA Human Drugs and TTD	32	23	https://conductscience.org/library/drugs?q=MONDO_0004976
major depressive disorder	Phase 2	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0002009
bipolar disorder	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0004985
spinal cord injury	Phase 2/3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0043797
cerebellar ataxia	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0000437
melanoma	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005105
post-traumatic stress disorder	Phase 1/2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005146
Irritability	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0000737
anxiety	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0011918
autism spectrum disorder	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005258

1 to 10 of 31Source Open Targets

See all 31 diseases

Trials76

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02496767	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year	Phase 3	744	2020-06-19	riluzole	Its name	ClinicalTrials.gov
NCT00868166	Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS	Phase 3	512	2019-02-15	riluzole	Its name	ClinicalTrials.gov
NCT01204918	Efficacy and Tolerability of Riluzole in Treatment Resistant Depression	Phase 2	104	2018-02-08	riluzole	Its name	ClinicalTrials.gov
NCT00376220	A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression	Phase 2	94	2017-04-11	riluzole	Its name	ClinicalTrials.gov
NCT02118727	Therapy in Amyotrophic Lateral Sclerosis (TAME)	Phase 2	89	2022-11-29	riluzole	Its name	ClinicalTrials.gov
NCT00818389	Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	Phase 2/3	84	2011-04-19	riluzole	Its name	ClinicalTrials.gov
NCT00251303	Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders	Phase 2	78	2014-07-15	riluzole	Its name	ClinicalTrials.gov
NCT02155829	Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)	Phase 1/2	75	2020-09-25	riluzole	Its name	ClinicalTrials.gov
NCT02238626	Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Phase 2	70	2021-11-05	riluzole	Its name	ClinicalTrials.gov
NCT04819438	Riluzole Orodispersible Film Replicate Bioavailability	Phase 1	54	2025-05-02	riluzole	Its name	ClinicalTrials.gov

1 to 10 of 76

See all 76 trials

Comparisons in its trials30

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Olesoxime vs Placebo Comparator: deaths from any cause	79 of 259	80 of 253	512	NCT00868166	Trial comparisons
Olesoxime vs Placebo Comparator: serious adverse events	68 of 259	65 of 253	512	NCT00868166	Trial comparisons
Riluzole Orodispersible Film (Test) vs Rilutek® (Reference): deaths from any cause	0 of 52	0 of 53	105	NCT04819438	Trial comparisons
Riluzole Orodispersible Film (Test) vs Rilutek® (Reference): serious adverse events	0 of 52	0 of 53	105	NCT04819438	Trial comparisons
Active Treatment Group vs Inactive/Placebo Group: serious adverse events	0 of 47	0 of 47	94	NCT00376220	Trial comparisons
Memantine vs Placebo: deaths from any cause	3 of 58	3 of 31	89	NCT02118727	Trial comparisons
Memantine vs Placebo: serious adverse events	8 of 58	3 of 31	89	NCT02118727	Trial comparisons
Lithium + Riluzole vs Placebo + Riluzole: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)	18 of 40	14 of 44	84	NCT00818389	Trial comparisons
Lithium + Riluzole vs Placebo + Riluzole: serious adverse events	10 of 40	8 of 44	84	NCT00818389	Trial comparisons
Riluzole vs Placebo: deaths from any cause	0 of 37	0 of 38	75	NCT02155829	Trial comparisons

1 to 10 of 30

See all 30 comparisons in its trials

Papers from its trials57

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34145880	RESULT	1	PubMed
29453787	RESULT	1	PubMed
24356715	RESULT	1	PubMed
23952636	RESULT	1	PubMed
23295632	RESULT	1	PubMed
22985379	RESULT	2	PubMed
21059347	RESULT	1	PubMed
19956089	RESULT	1	PubMed
42304135	DERIVED	1	PubMed
41086299	DERIVED	1	PubMed

1 to 10 of 57

See all 57 papers from its trials

Tests in its trials6

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Verbal Learning	2	1	ConductCognition
Continuous Performance Test	1	1	ConductCognition
Paced Visual Serial Addition Test	1	0	ConductCognition
Symbol Coding	1	1	ConductCognition
Verbal Fluency	1	1	ConductCognition
Vocabulary Test	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL744

GET https://conductscience.org/api/drugs/v1/CHEMBL744/diseases?page=2

API reference For AI assistants